San Francisco and Los Angeles-based tech attorney and angel investor Ben Lyon is a board member of the Silicon Valley Association of General Counsel and the California State Bar. Ben Lyon was the VP and general counsel for Immix Biophrama, Inc., which has made big strides in cancer drug development.
Immix Biopharma, Inc. has designed a drug in the first-class combination therapy that induces apoptosis and reduces cancer evolvability and resistance. Known as IMX-110, the drug contains NF-kB/Stat3/pan-kinase inhibitor curcumin and doxorubicin inserted in a nano delivery system to enable tumor penetration. IMX-110 can deliver more payload to tumors and other cell populations because it can be bound to several targeting moieties. Preclinically, the drug has worked for multiple myeloma, colorectal, triple-negative breast, pancreatic, and ovarian tumor models.
IMX-110 was used on a patient with stage-four leiomyosarcoma, and the trial was able to reach the six-month Progression-Free Survival (PFS) time point. The six-month PFS is an essential duration of response, and the stage is a relatively strong indicator of how effective a drug is. The aforementioned patient was treated with doxorubicin and twelve other drugs, but these were not as effective as IMX-110.
He has also been involved in independent international film production and is starting to assist film industries located in Central Europe.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.